Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

Wegovy and Novo Nordisk’s (NVO) Ozempic has been resolved. Semaglutide injections, which have become a popular treatment option for weight loss as well as Type 2 diabetes, have been considered to be ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

“We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding current and projected nationwide ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk's weight-loss medications Wegovy and Ozempic has been resolved, according to its website. The FDA announcement confirms ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...